Long‐term efficacy of canakinumab in hyperimmunoglobulin D syndrome.
In: International Journal of Rheumatic Diseases, Jg. 27 (2024), Heft 1, S. 1-4
Online
academicJournal
Zugriff:
Hyperimmunoglobulin D syndrome (HIDS) is a rare autoinflammatory disorder with autosomal recessive inheritance. It is caused by specific mutations in the mevalonate kinase gene (MVK). No treatment specific to HIDS has been approved to date; however, nonsteroidal anti‐inflammatory drugs, steroids, colchicine, tumor necrosis factor‐α inhibitors, and anti‐interleukin‐1 treatments are used, based on case reports and observational studies. Herein, we report a case with recurrent fever and arthritis attacks who did not respond to anakinra and was successfully treated with canakinumab. Long‐term remission was achieved without any side effects with 300 mg canakinumab treatment every 4 weeks for 5 years. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Rheumatic Diseases is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Long‐term efficacy of canakinumab in hyperimmunoglobulin D syndrome.
|
---|---|
Autor/in / Beteiligte Person: | Ozdemir Isik, Ozlem ; Karadag, Duygu Temiz ; Tekeoglu, Senem ; Yazici, Ayten ; Cefle, Kıvanc ; Cefle, Ayse |
Link: | |
Zeitschrift: | International Journal of Rheumatic Diseases, Jg. 27 (2024), Heft 1, S. 1-4 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 1756-1841 (print) |
DOI: | 10.1111/1756-185X.14857 |
Schlagwort: |
|
Sonstiges: |
|